Vandel B, Vandel S, Jounet J M, Allers G, Volmat R
Eur J Clin Pharmacol. 1982;22(1):15-20. doi: 10.1007/BF00606419.
Thirty one in-patients suffering from depression were treated orally with clomipramine (C1) at various dosage, for 28 days, after a "wash-out" period of three days. In 17 patients receiving 75 mg per day of C1, steady state plasma levels of C1 were reached at Day 14, and steady state plasma levels of its active metabolite, desmethylclomipramine (DMC1), were reached at Day 21. In contrast, in 7 other patients receiving a dosage increasing to 150 mg per day at Day 7, mean plasma levels of C1 and DMC1 continued to rise during the entire treatment period. At the steady state, a correlation was found between C1 dosage expressed as mg kg body weight and the plasma concentration of C1 and DMC1. Factors such as tobacco and alcohol consumption seem to modify the C1/DMC1 ratio. A comparison of clinical response with plasma levels of C1, DMC1 and C1 + DMC1 showed a significant negative linear correlation.
31名抑郁症住院患者在经过3天的“洗脱期”后,口服不同剂量的氯米帕明(C1),持续28天。在17名每天服用75毫克C1的患者中,第14天达到C1的稳态血浆水平,其活性代谢物去甲氯米帕明(DMC1)的稳态血浆水平在第21天达到。相比之下,在另外7名患者中,第7天剂量增加至每天150毫克,在整个治疗期间C1和DMC1的平均血浆水平持续上升。在稳态时,以毫克/千克体重表示的C1剂量与C1和DMC1的血浆浓度之间存在相关性。吸烟和饮酒等因素似乎会改变C1/DMC1比率。临床反应与C1、DMC1和C1 + DMC1血浆水平的比较显示出显著的负线性相关性。